bis (3-morpholinopropyl) fumarate | 1448896-87-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: bis (3-morpholinopropyl) fumarate
• 英文别名: bis(3-morpholin-4-ylpropyl) (E)-but-2-enedioate
• CAS: 1448896-87-4
• 化学式: C₁₈H₃₀N₂O₆
• 分子量: 370.446
• InChiKey: PYJKGMKKQFTSEK-ONEGZZNKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  26
• 可旋转键数：
  12
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  77.5
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  4-(3-羟丙基)吗啉 、 富马酸 在 4-二甲氨基吡啶 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 生成 bis (3-morpholinopropyl) fumarate
  参考文献：
  名称：

  MORPHOLINOALKYL FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE

  摘要：

  Morpholino烯丙酸烷基酯，包含该类化合物的药物组合物，以及使用Morpholino烯丙酸烷基酯和药物组合物治疗神经退行性、炎症性和自身免疫性疾病的方法被披露，这些疾病包括多发性硬化症、牛皮癣、肠易激综合征、溃疡性结肠炎、关节炎、慢性阻塞性肺疾病、哮喘、帕金森病、亨廷顿病和肌萎缩侧索硬化症。

  公开号：

  US20130203753A1

文献信息

• TREATMENT OF MULTIPLE SCLEROSIS AND PSORIASIS USING PRODRUGS OF METHYL HYDROGEN FUMARATE
  申请人：XenoPort, Inc.

  公开号：EP2854795A1

  公开（公告）日：2015-04-08
• Morpholinoalkyl Fumarate Compounds, Pharmaceutical Compositions, and Methods of Use
  申请人：XenoPort, Inc.

  公开号：US20140051705A1

  公开（公告）日：2014-02-20

  Morpholinoalkyl fumarates, pharmaceutical compositions comprising the morpholinoalkyl fumarates, and methods of using morpholinoalkyl fumarates and pharmaceutical compositions for treating neurodegenerative, inflammatory, and autoimmune disorders including multiple sclerosis, psoriasis, irritable bowel disorder, ulcerative colitis, arthritis, chronic obstructive pulmonary disease, asthma, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis are disclosed.
• US8952006B2
  申请人：——

  公开号：US8952006B2

  公开（公告）日：2015-02-10
• [EN] MORPHOLINOALKYL FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE<br/>[FR] COMPOSÉS DE FUMARATE DE MORPHOLINOALKYLE, COMPOSITIONS PHARMACEUTIQUES ET PROCÉDÉS D'UTILISATION
  申请人：XENOPORT INC

  公开号：WO2013119791A1

  公开（公告）日：2013-08-15

  Morpholinoalkyl fumarates, pharmaceutical compositions comprising the morpholinoalkyl fumarates, and methods of using morpholinoalkyl fumarates and pharmaceutical compositions for treating neurodegenerative, inflammatory, and autoimmune disorders including multiple sclerosis, psoriasis, irritable bowel disorder, ulcerative colitis, arthritis, chronic obstructive pulmonary disease, asthma, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis are disclosed.
• [EN] TREATMENT OF MULTIPLE SCLEROSIS AND PSORIASIS USING PRODRUGS OF METHYL HYDROGEN FUMARATE<br/>[FR] TRAITEMENT DE LA SCLÉROSE EN PLAQUES ET DU PSORIASIS AU MOYEN DE PROMÉDICAMENTS DE FUMARATE DE MÉTHYLE-HYDROGÈNE
  申请人：XENOPORT INC

  公开号：WO2013181451A1

  公开（公告）日：2013-12-05

  Improved methods of treating multiple sclerosis and/or psoriasis using prodrugs of methyl hydrogen fumarate are disclosed. The methods comprise administering certain prodrugs of methyl hydrogen fumarate. The methods are able to achieve high blood plasma concentrations of the active metabolite, methyl hydrogen fumarate, without causing significant gastrointestinal irritation. New prodrugs of methyl hydrogen fumarate are also disclosed.